Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.36 |
| ▸ | MTOR | P42345 | 8/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 4/20 | 0.33 |
| ▸ | PDE9A | O76083 | 4/20 | 0.33 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.33 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.33 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876260 | 0.91 | PIK3CA (0.36) | PIK3CAMTORPDE1BPDE1CPIK3CG | |
| SCHEMBL25876255 | 0.83 | PLK4 (0.45) | — | |
| SCHEMBL25876132 | 0.82 | PIK3CA (0.34) | PIK3CAMTORPDE1BPDE1CPIK3CG | |
| SCHEMBL25876131 | 0.82 | PDE9A (0.34) | PIK3CAMTORPDE1BPDE1CPIK3CG | |
| SCHEMBL25876052 | 0.78 | PDE9A (0.34) | PDE1BPDE1CPDE9A | |
| SCHEMBL25876258 | 0.78 | PIK3CA (0.36) | PIK3CAMTORPDE1BPDE1CPIK3CG | |
| SCHEMBL25876051 | 0.78 | PDE9A (0.35) | PDE1BPDE1CPDE9A | |
| SCHEMBL25875917 | 0.75 | PDE2A (0.40) | PIK3CA | |
| SCHEMBL25875863 | 0.74 | PDE2A (0.41) | — | |
| SCHEMBL25876341 | 0.73 | TEAD1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PIK3CA 487/4885MTOR 390/4885PDE1B 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.